Liposomal extended-release bupivacaine for postsurgical analgesia

: When physicians consider which analgesia to use postsurgery, the primary goal is to relieve pain with minimal adverse side effects. Bupivacaine, a commonly used analgesic, has been formulated into an aqueous suspension of multivesicular liposomes that provide long-lasting analgesia for up to 72 hours, while avoiding the adverse side effects of opioids. The increased efficacy of liposomal extended-release bupivacaine, compared to bupivacaine hydrochloride, has promoted its usage in a variety of surgeries including hemorrhoidectomy, bunionectomy, inguinal hernia repair, total knee arthroplasty, and augmentation mammoplasty. However, like other bupivacaine formulations, the liposomal extended-release bupivacaine does have some side effects. In this brief review, we provide an update of the current knowledge in the use of bupivacaine for postsurgical analgesia. bunionectomy, repair, total arthro-plasty, augmentation mammoplasty,

[1]  S. Daniels,et al.  Impact of local administration of liposome bupivacaine for postsurgical analgesia on wound healing: a review of data from ten prospective, controlled clinical studies. , 2013, Clinical therapeutics.

[2]  S. Ramamoorthy,et al.  The Safety of Liposome Bupivacaine, A Novel Local Analgesic Formulation , 2013, The Clinical journal of pain.

[3]  Stephen M. Cohen,et al.  Extended pain relief trial utilizing infiltration of Exparel®, a long-acting multivesicular liposome formulation of bupivacaine: a Phase IV health economic trial in adult patients undergoing open colectomy , 2012, Journal of pain research.

[4]  E. Viscusi,et al.  A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. , 2012, The Knee.

[5]  A. Camm,et al.  Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers , 2012, Journal of clinical pharmacology.

[6]  S. Ramamoorthy,et al.  Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting , 2012, Current medical research and opinion.

[7]  P. Chahar,et al.  Liposomal bupivacaine: a review of a new bupivacaine formulation , 2012, Journal of pain research.

[8]  Hyo-Suk Park,et al.  Triamcinolone decreases bupivacaine toxicity to intervertebral disc cell in vitro. , 2012, The spine journal : official journal of the North American Spine Society.

[9]  S. Ramamoorthy,et al.  Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia , 2012, Journal of pain research.

[10]  P. White,et al.  A Double-Blind, Randomized, Active-Controlled Study for Post-Hemorrhoidectomy Pain Management with Liposome Bupivacaine, a Novel Local Analgesic Formulation , 2012, The American surgeon.

[11]  F. Savoie,et al.  Hyaluronan Protects Bovine Articular Chondrocytes Against Cell Death Induced by Bupivacaine at Supraphysiologic Temperatures , 2012, The American journal of sports medicine.

[12]  P. Pronovost,et al.  Does Patient Perception of Pain Control Affect Patient Satisfaction Across Surgical Units in a Tertiary Teaching Hospital? , 2012, American journal of medical quality : the official journal of the American College of Medical Quality.

[13]  P. Newton,et al.  The Safety of EXPAREL ® (Bupivacaine Liposome Injectable Suspension) Administered by Peripheral Nerve Block in Rabbits and Dogs , 2012, Journal of drug delivery.

[14]  B. Feeley,et al.  Effects of Local Anesthetics on Articular Cartilage , 2011, The American journal of sports medicine.

[15]  P. Newton,et al.  The safety and tolerability evaluation of DepoFoam bupivacaine (bupivacaine extended-release liposome injection) administered by incision wound infiltration in rabbits and dogs , 2011, Expert opinion on investigational drugs.

[16]  S. Daniels,et al.  A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy , 2011, Advances in therapy.

[17]  D. Docheva,et al.  Bupivacaine, ropivacaine, and morphine: comparison of toxicity on human hamstring-derived stem/progenitor cells , 2011, Knee Surgery, Sports Traumatology, Arthroscopy.

[18]  N. Polissar,et al.  Risk factors for chondrolysis of the glenohumeral joint: a study of three hundred and seventy-five shoulder arthroscopic procedures in the practice of an individual community surgeon. , 2011, The Journal of bone and joint surgery. American volume.

[19]  James D. Kang,et al.  Bupivacaine decreases cell viability and matrix protein synthesis in an intervertebral disc organ model system. , 2011, The spine journal : official journal of the North American Spine Society.

[20]  S. Matecki,et al.  N-Acetylcysteine Protects against Bupivacaine-induced Myotoxicity Caused by Oxidative and Sarcoplasmic Reticulum Stress in Human Skeletal Myotubes , 2010, Anesthesiology.

[21]  C. Zhang,et al.  Concentration-dependent bupivacaine myotoxicity in rabbit extraocular muscle. , 2010, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[22]  Jordan Z. Buchko,et al.  Chondrolysis of the glenohumeral joint after infusion of bupivacaine through an intra-articular pain pump catheter: a report of 18 cases. , 2010, Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association.

[23]  M. Szczodry,et al.  In vivo effects of single intra-articular injection of 0.5% bupivacaine on articular cartilage. , 2010, The Journal of bone and joint surgery. American volume.

[24]  James D. Kang,et al.  Effect of bupivacaine on intervertebral disc cell viability. , 2010, The spine journal : official journal of the North American Spine Society.

[25]  F. Sztark,et al.  Age-dependent Bupivacaine-induced Muscle Toxicity during Continuous Peripheral Nerve Block in Rats , 2009, Anesthesiology.

[26]  M. Akhtar,et al.  Wound infiltration with Bupivacaine versus Ketorolac for postoperative pain relief in minor to moderate surgeries. , 2009, JPMA. The Journal of the Pakistan Medical Association.

[27]  K. Smolková,et al.  Erythropoietin Protects against Local Anesthetic Myotoxicity during Continuous Regional Analgesia , 2009, Anesthesiology.

[28]  G. Fanelli,et al.  Pharmacology, toxicology, and clinical use of new long acting local anesthetics, ropivacaine and levobupivacaine. , 2008, Acta bio-medica : Atenei Parmensis.

[29]  C. H. Coyle,et al.  The in vitro effects of bupivacaine on articular chondrocytes. , 2008, The Journal of bone and joint surgery. British volume.

[30]  S. Datta,et al.  Opioid complications and side effects. , 2008, Pain physician.

[31]  Matthew H Samore,et al.  Opioid-Related Adverse Drug Events in Surgical Hospitalizations: Impact on Costs and Length of Stay , 2007, The Annals of pharmacotherapy.

[32]  J. Butterworth,et al.  Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments , 2006, Anesthesia and analgesia.

[33]  A. Borgeat,et al.  Interscalene Brachial Plexus Anesthesia With Ropivacaine 5 mg/mL and Bupivacaine 5 mg/mL: Effects on Electrocardiogram , 2004, Regional Anesthesia & Pain Medicine.

[34]  S. Brown,et al.  Local anesthetic infusion pump systems adverse events reported to the Food and Drug Administration. , 2004, Anesthesiology.

[35]  R. Fink,et al.  Differential effects of bupivacaine on intracellular Ca2+ regulation: potential mechanisms of its myotoxicity. , 2002, Anesthesiology.

[36]  K. Speer,et al.  Interscalene Brachial Plexus Block with a Continuous Catheter Insertion System and a Disposable Infusion Pump , 2000, Anesthesia and analgesia.

[37]  B. Veering,et al.  Cardiovascular and Central Nervous System Effects of Intravenous Levobupivacaine and Bupivacaine in Sheep , 1998, Anesthesia and analgesia.

[38]  J. Eledjam,et al.  Succinylcholine does not worsen bupivacaine-induced cardiotoxicity in pentobarbital-anaesthetized dogs , 1992, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[39]  B. Covino,et al.  Comparative Systemic Toxicity of Convulsant and Supraconvulsant Doses of Intravenous Ropivacaine, Bupivacaine, and Lidocaine in the Conscious Dog , 1989, Anesthesia and analgesia.

[40]  P. Rosenberg,et al.  Continuous interscalene brachial plexus block: clinical efficacy, technical problems and bupivacaine plasma concentrations , 1989, Acta anaesthesiologica Scandinavica.

[41]  L. Hondeghem,et al.  Mechanism for Bupivacaine Depression of Cardiac Conduction: Fast Block of Sodium Channels during the Action Potential with Slow Recovery from Block during Diastole , 1985, Anesthesiology.

[42]  M. Akbari,et al.  Bupivacaine injection myotoxicity on extraocular muslces. A strabismus alternative treatment: extended histological changes induced in a rabbit model. , 2012, Binocular vision & strabology quarterly, Simms-Romano's.

[43]  S. Bergese,et al.  The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study. , 2012, Aesthetic surgery journal.

[44]  N. Boos,et al.  Bupivacaine--the deadly friend of intervertebral disc cells? , 2011, The spine journal : official journal of the North American Spine Society.

[45]  R. Gristwood.  Cardiac and CNS toxicity of levobupivacaine: strengths of evidence for advantage over bupivacaine. , 2002, Drug safety.

[46]  P. Myles,et al.  Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. , 2000, British journal of anaesthesia.